ClinicalTrials.Veeva

Menu

Development and Validation of a Disability Severity Index for CMT (6604)

University of Iowa logo

University of Iowa

Status

Completed

Conditions

Charcot Marie Tooth Disease

Study type

Observational

Funder types

Other
NIH

Identifiers

NCT01455623
INC-6604

Details and patient eligibility

About

It is necessary for outcome measures to accurately reflect the state of health of a person in order for clinical trials to show benefit. The most commonly used outcome measure for Charcot Marie Tooth Disease (CMT) is the CMT Neuropathy Score, which uses cutoffs of points designated as mild (0-10 points), moderate (11-20) or severe (21-36). These terms are arbitrary. This study is looking to base mild, moderate, and severe on what both people affected with CMT and those who provide for people with CMT consider appropriate.

Enrollment

291 patients

Sex

All

Ages

8+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • patients with CMT ages 8-100,

  • health care professionals who take care of patients with CMT.

    • Eligible patients will be patients that have joined the INC RDCRN Contact Registry. These will be patients or guardians with known or probable inherited neuropathies.
    • Eligible health care professionals who participate in the care of patients with inherited neuropathies (physicians, genetic counselors, physical and occupational therapists etc.) attending the 4th International CMT Consortium to be held in Potomac Maryland June 29-July 1, 2011.

Exclusion criteria

  • Does not read or speak English.

Trial design

291 participants in 2 patient groups

Health Care Provider
Description:
A person working within the field of CMT.
Patient with CMT
Description:
Any person of any age self-identifying as having CMT and belonging to the Inherited Neuropathies Consortium Contact Registry hosted by the Rare Disease Clinical Research Network.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems